This clinical trial is focused on studying ovarian cancer, specifically in patients who have a poor prognosis due to the cancer’s resistance to initial chemotherapy and incomplete surgical removal of the tumor. The study will explore the effectiveness of a new treatment approach using a combination of carboplatin and paclitaxel, which are chemotherapy drugs. These drugs are typically used to treat ovarian cancer, but this trial will test a new dosing schedule that involves more frequent, smaller doses, known as a “weekly dose-dense regimen.” The goal is to see if this new approach is more effective than the standard treatment, which involves larger doses given every three weeks.

In addition to carboplatin and paclitaxel, the study will also involve the use of bevacizumab, a medication that helps prevent the growth of blood vessels that supply the tumor, and filgrastim, which is used to boost white blood cell counts and help the body fight infections during chemotherapy. Some patients in the study will receive a placebo instead of bevacizumab to compare the effects. The trial aims to determine if the new treatment plan can improve outcomes for patients, such as increasing the chances of successful surgery and extending survival times.

Participants in the study will receive treatment over a period of up to 64 weeks. The study will monitor various outcomes, including the overall response to treatment, progression-free survival (the time during which the cancer does not get worse), and overall survival. The trial will also assess the quality of life of participants and gather information on any side effects experienced. The findings from this study could help improve treatment strategies for patients with ovarian cancer who have a poor prognosis.